Mark Schoenberg - Jan 31, 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 31, 2022
Transactions value $
-$10,415
Form type
4
Date filed
2/2/2022, 03:33 PM
Previous filing
Jan 28, 2022
Next filing
May 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +500 +2.26% 22.6K Jan 31, 2022 Direct F1
transaction URGN Ordinary Shares Sale -$2.08K -275 -1.22% $7.58 22.3K Jan 31, 2022 Direct F2
transaction URGN Ordinary Shares Options Exercise +2K +8.96% 24.3K Jan 31, 2022 Direct F1
transaction URGN Ordinary Shares Sale -$8.33K -1.1K -4.52% $7.58 23.2K Jan 31, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -500 -20% $0.00 2K Jan 31, 2022 Ordinary Shares 500 Direct F1, F3
transaction URGN Stock Option (right to buy) Award $0 +12.1K $0.00 12.1K Jan 31, 2022 Ordinary Shares 12.1K $7.72 Direct F4
transaction URGN Restricted Stock Units Award $0 +4K $0.00 4K Jan 31, 2022 Ordinary Shares 0 Direct F1, F5
transaction URGN Restricted Stock Options Exercise $0 -2K -33.33% $0.00 4K Jan 31, 2022 Ordinary Shares 2K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.
F4 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025
F5 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025
F6 The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.